Wegovy is available from £169 and Mounjaro is available from £179 - please see below for stock details

What is Wegovy?

Wegovy is a medicine intended to encourage weight loss, self-administered as an injection; it comes in pre-filled injection pens. It’s designed to assist individuals on their weight loss journey. It contains the active ingredient semaglutide, which mimics the body’s own hormone GLP-1 (“glucagon-like peptide 1”), and it regulates appetite and promotes feelings of fullness.

Wegovy is convenient as it only needs to be administered once a week, and is an option for adults with a body mass index (BMI) over 30, or those with a BMI over 27 who have other weight-related health conditions, as an addition to a reduced calorie diet and an increase in levels of physical activity.

Who can use it?

Wegovy is suitable for individuals who meet specific criteria and are seeking effective help with weight loss.

  • Adults with obesity (BMI over 30)

  • Adults who are overweight (BMI higher than 27) and have weight-related health conditions such as high blood pressure

Who can't use it?

Wegovy isn't suitable for:

  • People with a history of allergic reactions to semaglutide or any of the other ingredients in Wegovy

  • Those experiencing diabetic retinopathy

  • Individuals with kidney problems

  • Those at risk of pancreatitis

People with diabetes should talk to their NHS GP about weight loss medicines, because Wegovy could interact with other medicines prescribed for this condition.

How it works

Wegovy's active ingredient, semaglutide, mimics the body’s own hormone GLP-1, responsible for regulating appetite. By interacting with brain receptors, Wegovy helps control appetite, leading to reduced food cravings. When combined with a reduced calorie diet and increased physical activity, Wegovy supports effective weight loss.

Is Wegovy effective?

Clinical trials have demonstrated Wegovy's efficacy. Over 68 weeks, studies have shown Wegovy treatment contributed to a statistically significant reduction in body weight compared to a placebo (inactive medicine). Results also highlighted that 83.5% of Wegovy-treated patients achieved a 5% or more reduction in their body weight.

If, after 12 weeks of treatment at the maximum tolerated dose, Wegovy has not resulted in a reduction of your initial body mass index (BMI) by at least 5%, it may not be suitable for you. In such cases, the doctor will assess whether discontinuing its use would be the most appropriate course of action.

Frequently asked questions

Spread the cost with paypal pay in 3